Background: Sunitinib and Pazopanib are two metastatic renal cell carcinoma (MRCC) treatment alternatives, however the health system in Chile does not consider coverage for any. The cost-effectiveness versus relevant ...

Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to ...

Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to ...

The main goal of this work was to report the synthesis, characterization, and cytotoxicity study of a novel copper(II)-sunitinib complex, CuSun. It has been synthesized and characterized in solid state and in solution by ...

Introducción: Aproximadamente un tercio de los pacientes con cáncer de células renales (CCR) son diagnosticados cuando se encuentran cursando una etapa avanzada de la enfermedad, esto influye en la expectativa de vida ...

Alveolar soft-part sarcoma is a rare malignant entity with poor prognosis. Chemotherapy has limited activity in this type of sarcoma, we describe here the outcomes of the first case documented in our Institution with ...

Alveolar soft-part sarcoma is a rare malignant entity with poor prognosis. Chemotherapy has limited activity in this type of sarcoma, we describe here the outcomes of the first case documented in our Institution with ...

Esta monografia destina-se a realizar a Análise do Impacto Orçamentário do medicamento sunitinibe, um medicamento de alto custo, indicado para o Carcinoma de Células Renais Metastática, o tipo mais comum de câncer de rim. ...